155 related articles for article (PubMed ID: 34465534)
1. Association Between Metabolic Syndrome and Immunohistochemical Profile at Breast Cancer Diagnosis in Postmenopausal Women.
Motoki AH; Buttros DAB; Gaspar AL; Almeida-Filho BS; Carvalho-Pessoa E; Vespoli HDL; Nahas-Neto J; Nahas EAP
Clin Breast Cancer; 2022 Feb; 22(2):e253-e261. PubMed ID: 34465534
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women.
de Sousa Almeida-Filho B; De Luca Vespoli H; Pessoa EC; Machado M; Nahas-Neto J; Nahas EAP
J Steroid Biochem Mol Biol; 2017 Nov; 174():284-289. PubMed ID: 29031688
[TBL] [Abstract][Full Text] [Related]
3. Risk of metabolic syndrome in postmenopausal breast cancer survivors.
Buttros Dde A; Nahas EA; Vespoli Hde L; Uemura G; de Almeida Bda R; Nahas-Neto J
Menopause; 2013 Apr; 20(4):448-54. PubMed ID: 23149866
[TBL] [Abstract][Full Text] [Related]
4. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
5. Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study.
Agresti R; Meneghini E; Baili P; Minicozzi P; Turco A; Cavallo I; Funaro F; Amash H; Berrino F; Tagliabue E; Sant M
Breast Cancer Res Treat; 2016 May; 157(1):179-89. PubMed ID: 27117160
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D deficiency is associated with metabolic syndrome in postmenopausal women.
Schmitt EB; Nahas-Neto J; Bueloni-Dias F; Poloni PF; Orsatti CL; Petri Nahas EA
Maturitas; 2018 Jan; 107():97-102. PubMed ID: 29169589
[TBL] [Abstract][Full Text] [Related]
7. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
Crispo A; Montella M; Buono G; Grimaldi M; D'Aiuto M; Capasso I; Esposito E; Amore A; Nocerino F; Augustin LS; Giudice A; Di Bonito M; Giuliano M; Forestieri V; De Laurentiis M; Rinaldo M; Ciliberto G; De Placido S; Arpino G
Curr Res Transl Med; 2016; 64(1):15-20. PubMed ID: 27140595
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
9. Association between Metabolic Syndrome Risk Factors and Immunohistochemical Profile in Women with Breast Cancer.
Danesh H; Anbiaei R; Ziamajidi N; Farhadian M; Barartabar Z; Abbasalipourkabir R
Iran J Med Sci; 2023 Sep; 48(5):456-464. PubMed ID: 37786471
[TBL] [Abstract][Full Text] [Related]
10. The association between body mass index and immunohistochemical subtypes in breast cancer.
Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
Sun WY; Choi J; Cha YJ; Koo JS
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
13. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.
Ibrahim E; Al-Gahmi AM; Zeenelin AA; Zekri JM; Elkhodary TR; Gaballa HE; Fawzy EE; El sayed ME; Alzahrani MS
Med Oncol; 2009; 26(3):372-8. PubMed ID: 19034706
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome and outcomes following early-stage breast cancer.
Calip GS; Malone KE; Gralow JR; Stergachis A; Hubbard RA; Boudreau DM
Breast Cancer Res Treat; 2014 Nov; 148(2):363-77. PubMed ID: 25301086
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
17. Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.
Mitrović O; Čokić V; Đikić D; Budeč M; Vignjević S; Subotički T; Gulan M; Radović S; Furtula S
Target Oncol; 2014 Dec; 9(4):367-79. PubMed ID: 24272208
[TBL] [Abstract][Full Text] [Related]
18. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
19. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
20. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]